Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2Cl.Sr.6H2O |
Molecular Weight | 266.62 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.O.O.[Cl-].[Cl-].[Sr++]
InChI
InChIKey=AMGRXJSJSONEEG-UHFFFAOYSA-L
InChI=1S/2ClH.6H2O.Sr/h2*1H;6*1H2;/q;;;;;;;;+2/p-2
Molecular Formula | Sr |
Molecular Weight | 87.62 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Strontium ranelate is composed of an organic moiety (ranelic acid) and of two atoms of stable nonradioactive strontium. In vitro, strontium ranelate increases collagen and noncollagenic proteins synthesis by mature osteoblast enriched cells. The effects of strontium ranelate on bone formation were confirmed as strontium ranelate enhanced pre-osteoblastic cell replication. The stimulation by strontium ranelate of the replication of osteoprogenitor cell and collagen, as well as noncollagenic protein synthesis in osteoblasts, provides substantial evidence to categorize strontium ranelate as a bone-forming agent. In the isolated rat osteoclast assay, a pre-incubation of bone slices with strontium ranelate induced a dose- dependent inhibition of the bone resorbing activity of treated rat osteoclast. Strontium ranelate also dose-dependently inhibited, in a chicken bone marrow culture, the expression of both carbonic anhydrase II and the alpha-subunit of the vitronectin receptor. These effects showing that strontium ranelate significantly affects bone resorption due to a direct and/or matrix-mediated inhibition of osteoclast activity and also inhibits osteoclasts differentiation, are compatible with the profile of an anti-resorptive drug. Pharmacological and clinical studies suggest that strontium ranelate optimizes bone resorption and bone formation, resulting in increased bone mass, which may be of great value in the treatment of osteoporosis. Strontium ranelate is approved by EMA for the treatment of severe osteoporosis in postmenopausal women and in adult men.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PROTELOS Approved UseTreatment of severe osteoporosis:
- in postmenopausal women,
- in adult men,
at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance. In postmenopausal women, strontium ranelate reduces the risk of vertebral and hip fractures. Launch Date2004 |
Sample Use Guides
The recommended dose is one sachet containing 2 g of strontium ranelate once daily by oral administration.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27157549
Osteoblastic MC3TE-E1 cell cultures exposed to Strontium ranelate (SR) at 0.5 mM exhibited a decrease in both cell proliferation and cell viability in all time points assayed. High levels of protein and mRNA for Type I Collagen and Osteopontin were detected in cultures exposed to SR, particularly at 0.5 mM. SR allowed the expression of fibronectin in osteoblastic cell cultures as observed by epifluorescence analysis. The mineralized bone-like nodule formation was affected in a concentration-dependent manner by SR, with large bone-like nodules being detected in osteoblastic cell cultures exposed to SR at 0.5 mM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:14:35 GMT 2023
by
admin
on
Fri Dec 15 16:14:35 GMT 2023
|
Record UNII |
O09USB7Z44
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID00143067
Created by
admin on Fri Dec 15 16:14:35 GMT 2023 , Edited by admin on Fri Dec 15 16:14:35 GMT 2023
|
PRIMARY | |||
|
1594632
Created by
admin on Fri Dec 15 16:14:35 GMT 2023 , Edited by admin on Fri Dec 15 16:14:35 GMT 2023
|
PRIMARY | RxNorm | ||
|
36385
Created by
admin on Fri Dec 15 16:14:35 GMT 2023 , Edited by admin on Fri Dec 15 16:14:35 GMT 2023
|
PRIMARY | |||
|
C84182
Created by
admin on Fri Dec 15 16:14:35 GMT 2023 , Edited by admin on Fri Dec 15 16:14:35 GMT 2023
|
PRIMARY | |||
|
C45678
Created by
admin on Fri Dec 15 16:14:35 GMT 2023 , Edited by admin on Fri Dec 15 16:14:35 GMT 2023
|
CONCEPT | Industrial Aid | ||
|
O09USB7Z44
Created by
admin on Fri Dec 15 16:14:35 GMT 2023 , Edited by admin on Fri Dec 15 16:14:35 GMT 2023
|
PRIMARY | |||
|
C025700
Created by
admin on Fri Dec 15 16:14:35 GMT 2023 , Edited by admin on Fri Dec 15 16:14:35 GMT 2023
|
PRIMARY | |||
|
SUB35895
Created by
admin on Fri Dec 15 16:14:35 GMT 2023 , Edited by admin on Fri Dec 15 16:14:35 GMT 2023
|
PRIMARY | |||
|
100000128616
Created by
admin on Fri Dec 15 16:14:35 GMT 2023 , Edited by admin on Fri Dec 15 16:14:35 GMT 2023
|
PRIMARY | |||
|
159250
Created by
admin on Fri Dec 15 16:14:35 GMT 2023 , Edited by admin on Fri Dec 15 16:14:35 GMT 2023
|
PRIMARY | |||
|
m10240
Created by
admin on Fri Dec 15 16:14:35 GMT 2023 , Edited by admin on Fri Dec 15 16:14:35 GMT 2023
|
PRIMARY | Merck Index | ||
|
DBSALT002644
Created by
admin on Fri Dec 15 16:14:35 GMT 2023 , Edited by admin on Fri Dec 15 16:14:35 GMT 2023
|
PRIMARY | |||
|
10025-70-4
Created by
admin on Fri Dec 15 16:14:35 GMT 2023 , Edited by admin on Fri Dec 15 16:14:35 GMT 2023
|
PRIMARY | |||
|
O09USB7Z44
Created by
admin on Fri Dec 15 16:14:35 GMT 2023 , Edited by admin on Fri Dec 15 16:14:35 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |